AH 6809

Confirm delete?

AH 6809

Zoom

Cat No: 14050

Biochemicals - Receptor Pharmacology

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.{8322} AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.{3391} It...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

6-isopropoxy-9-oxoxanthene-2-carboxylic acid

Correlated keywords:

EP1 EP2 receptors antagonists AH6809 DP PGE2 prostaglandins ah-6809

Product Overview:
AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.{8322} AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.{3391} It also blocks the accumulation of Ca2+ in Xenopus oocytes expressing the human EP1 receptor.{3176} In the human and guinea pig, the activity profile of AH 6809 is similar to that of SC-19220, but it is somewhat more potent.{3409} In the mouse, AH 6809 has the highest affinity for the EP2 receptor, but also acts as a weak ligand at the murine EP1 and DP1 receptors.{6640} In whole human platelets, AH 6809 is an effective antagonist of the antiaggregatory actions of PGD2, but not PGI2, with an EC50 of about 5 x 10−5 M.{3319}

Size	1 mg
Shipping	wet ice
CAS Number	33458-93-4
Molecular Formula	C₁₇H₁₄O₅
SMILES	CC(OC1=CC(OC2=CC=C(C(O)=O)C=C2C3=O)=C3C=C1)C
Molecular Weight	298,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2933.49
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.